157 related articles for article (PubMed ID: 29956845)
21. The role of bone marrow study in diagnosis and prognosis of myelodysplastic syndrome.
Saad ST; Vassallo J; Arruda VA; Lorand-Metze I
Pathologica; 1994 Feb; 86(1):47-51. PubMed ID: 8072801
[TBL] [Abstract][Full Text] [Related]
22. Interobserver variance in myelodysplastic syndromes with less than 5 % bone marrow blasts: unilineage vs. multilineage dysplasia and reproducibility of the threshold of 2 % blasts.
Font P; Loscertales J; Soto C; Ricard P; Novas CM; Martín-Clavero E; López-Rubio M; Garcia-Alonso L; Callejas M; Bermejo A; Benavente C; Ballesteros M; Cedena T; Calbacho M; Urbina R; Villarrubia J; Gil S; Bellón JM; Diez-Martin JL; Villegas A
Ann Hematol; 2015 Apr; 94(4):565-73. PubMed ID: 25387664
[TBL] [Abstract][Full Text] [Related]
23. Biomarkers of angiogenesis as prognostic factors in myelodysplastic syndrome patients treated with hypomethylating agents.
Kim CK; Han DH; Ji YS; Lee MS; Min CW; Park SK; Kim SH; Yun J; Kim HJ; Kim KH; Lee KT; Won JH; Hong DS; Kim HK
Leuk Res; 2016 Nov; 50():21-28. PubMed ID: 27639703
[TBL] [Abstract][Full Text] [Related]
24. Incidence and prognostic significance of karyotype abnormalities in de novo primary myelodysplastic syndromes: a study on 331 patients from a single institution.
Bernasconi P; Klersy C; Boni M; Cavigliano PM; Calatroni S; Giardini I; Rocca B; Zappatore R; Caresana M; Quarna J; Lazzarino M; Bernasconi C
Leukemia; 2005 Aug; 19(8):1424-31. PubMed ID: 15920496
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of blast cell counts in dysplastic bone marrow disorders (MDS and CMML I) with concomitant fibrosis.
Machherndl-Spandl S; Sega W; Bösmüller H; Germing U; Gruber Ch; Nachtkamp K; Reinecke P; Sperr WR; Wimazal F; Müllauer L; Sotlar K; Horny HP; Tüchler H; Valent P; Krieger O
Ann Hematol; 2014 Jan; 93(1):57-64. PubMed ID: 24241126
[TBL] [Abstract][Full Text] [Related]
26. The incorporation of comorbidities in the prognostication of patients with lower-risk myelodysplastic syndrome.
Falantes JF; Márquez-Malaver FJ; Knight T; Calderón-Cabrera C; Martino ML; González J; Montero I; Espigado I; Pérez-Simón JA
Leuk Lymphoma; 2017 Aug; 58(8):1893-1902. PubMed ID: 27951729
[TBL] [Abstract][Full Text] [Related]
27. The level of bone marrow WT1 message is a useful marker to differentiate myelodysplastic syndromes with low blast percentage from cytopenia due to other reasons.
Baba M; Hata T; Tsushima H; Mori S; Sasaki D; Turuta K; Hasegawa H; Ando K; Sawayama Y; Imanishi D; Taguchi J; Yanagihara K; Tomonaga M; Kamihira S; Miyazaki Y
Intern Med; 2015; 54(5):445-51. PubMed ID: 25758068
[TBL] [Abstract][Full Text] [Related]
28. DNA repair gene expressions are related to bone marrow cellularity in myelodysplastic syndrome.
Ribeiro HL; Maia ARS; de Oliveira RTG; Costa MB; Farias IR; de Paula Borges D; de Sousa JC; Magalhães SMM; Pinheiro RF
J Clin Pathol; 2017 Nov; 70(11):970-980. PubMed ID: 28554891
[TBL] [Abstract][Full Text] [Related]
29. Histological and cytogenetic characterization of bone marrow in relation to prognosis and diagnosis of myelodysplastic syndromes.
Sakuma T; Hayashi Y; Kanomata N; Murayama T; Matsui T; Kajimoto K; Hanioka K; Chihara K; Maeda S
Pathol Int; 2006 Apr; 56(4):191-9. PubMed ID: 16634964
[TBL] [Abstract][Full Text] [Related]
30. High PRAME expression is associated with poor survival and early disease progression in myelodysplastic syndromes with a low bone marrow blast percentage.
Shiseki M; Ishii M; Ohwashi M; Wang YH; Tanaka N; Osanai S; Yoshinaga K; Mori N; Tanaka J
Leuk Lymphoma; 2021 Oct; 62(10):2448-2456. PubMed ID: 34013846
[TBL] [Abstract][Full Text] [Related]
31. Quantity of clonal cells detected by conventional cytogenetic analysis correlates with bone marrow blasts and survival in myelodysplastic syndromes.
Kim M; Chung S; See CJ; Yoon SS; Kim BK; Kim HK; Lee DS
Leuk Res; 2012 Feb; 36(2):163-8. PubMed ID: 21920602
[TBL] [Abstract][Full Text] [Related]
32. A four-parameter index of marrow dysplasia has predictive value for survival in myelodysplastic syndromes.
Tassin F; Dewé W; Schaaf N; Herens C; Ravoet C; Albert A; Beguin Y; Paulus JM
Leuk Lymphoma; 2000 Feb; 36(5-6):485-96. PubMed ID: 10784393
[TBL] [Abstract][Full Text] [Related]
33. Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome.
Yue G; Hao S; Fadare O; Baker S; Pozdnyakova O; Galili N; Woda BA; Raza A; Wang SA
Leuk Res; 2008 Apr; 32(4):553-8. PubMed ID: 17888511
[TBL] [Abstract][Full Text] [Related]
34. [Evolution of acute leukemia in myelodysplastic syndromes: prognostic histopathological factors in a series of bone marrow biopsies].
Navone R; Ranco V; Pich A
Pathologica; 1991; 83(1083):55-63. PubMed ID: 1866200
[TBL] [Abstract][Full Text] [Related]
35. Detection of risk groups in myelodysplastic syndromes. A multicenter study.
Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I
Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460
[TBL] [Abstract][Full Text] [Related]
36. The myelodysplastic syndromes: analysis of prognostic factors and comparison of prognostic systems in 128 Chinese patients from a single institution.
Zhao WL; Xu L; Wu W; Yan H; Tang W; Hu J; Chen Y; Li JM; Zeng XY; Xiong SM; Shen ZX; Chen Z; Wang ZY; Chen SJ
Hematol J; 2002; 3(3):137-44. PubMed ID: 12111649
[TBL] [Abstract][Full Text] [Related]
37. Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system.
Tong WG; Quintás-Cardama A; Kadia T; Borthakur G; Jabbour E; Ravandi F; Faderl S; Wierda W; Pierce S; Shan J; Bueso-Ramos C; Kantarjian H; Garcia-Manero G
Cancer; 2012 Sep; 118(18):4462-70. PubMed ID: 22252728
[TBL] [Abstract][Full Text] [Related]
38. Reduced PLCG1 expression is associated with inferior survival for myelodysplastic syndromes.
Shiseki M; Ishii M; Miyazaki M; Osanai S; Wang YH; Yoshinaga K; Mori N; Tanaka J
Cancer Med; 2020 Jan; 9(2):460-468. PubMed ID: 31755660
[TBL] [Abstract][Full Text] [Related]
39. The myelodysplastic syndromes flow cytometric score: a three-parameter prognostic flow cytometric scoring system.
Alhan C; Westers TM; Cremers EM; Cali C; Witte BI; Ossenkoppele GJ; van de Loosdrecht AA
Leukemia; 2016 Mar; 30(3):658-65. PubMed ID: 26503643
[TBL] [Abstract][Full Text] [Related]
40. Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes.
Verburgh E; Achten R; Maes B; Hagemeijer A; Boogaerts M; De Wolf-Peeters C; Verhoef G
J Clin Oncol; 2003 Jan; 21(2):273-82. PubMed ID: 12525519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
